# A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease

> **NCT02245412** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 25 (actual)

## Conditions studied

- Acute Graft-Versus-Host Disease
- GIGVHD

## Interventions

- **BIOLOGICAL:** ALXN1007 10 mg/kg once weekly
- **BIOLOGICAL:** ALXN1007 20 mg/kg once weekly
- **BIOLOGICAL:** ALXN1007 20 mg/kg twice weekly

## Key facts

- **NCT ID:** NCT02245412
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-14
- **Primary completion:** 2017-02-27
- **Final completion:** 2017-02-27
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Terminated early at the Sponsor's discretion, not due to safety concerns.
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02245412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02245412, "A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02245412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*